# A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

> **NCT03255382** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 120 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Fumaderm
- **DRUG:** risankizumab

## Key facts

- **NCT ID:** NCT03255382
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2018-07-06
- **Final completion:** 2018-07-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255382, "A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03255382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*